ERBB2 and breast carcinoma: In a phase I study, everolimus, trastuzumab, and paclitaxel combination therapy of HER2-positive breast cancer showed promising results with an ORR of 44% and median PFS of 34 weeks (Table 2); however, grade 3 to 4 neutropenia was common in patients [164].